------------------------------
------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
March 6, 1996
XYTRONYX, INC.
--------------------------------
(Exact name of registrant as specified in its charter)
Delaware
--------------------------------
(State or other jurisdiction of incorporation)
0-14838 36-3258753
------------------ ------------------------
(Commissioner File Number) (IRS Employer Identification Number)
6555 Nancy Ridge Drive
Suite 200
San Diego, California 92121
--------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (619) 550-3900
--------------
Item 5. Other Events.
The News Release dated March 6, 1996 regarding letter of intent to
acquire option to purchase Binary Therapeutics, Inc., filed as Exhibit 99.47
hereto, is hereby incorporated into this Report by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) EXHIBITS. The following exhibit accompanies this Report:
Exhibit
Number Exhibit Description
------ -------------------
99.47 News Release dated March 6, 1996 regarding letter of intent
to acquire option to purchase Binary Therapeutics, Inc
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
XYTRONYX, INC.
By: /s/ DALE SANDER
----------------------------
Dale Sander
Chief Financial Officer
Date: March 12, 1996
2
INDEX TO EXHIBITS
Exhibit Sequentially
Number Description of Exhibit Numbered Page
- ------ ---------------------- -------------
99.47 News Release dated March 6, 1996 regarding letter
of intent to acquire option to purchase Binary
Therapeutics, Inc
3